EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) have been used as first-line treatment of advanced NSCLC patients harboring EGFR mutations, which successfully improved the response rate (RR) and prolonged survival compared with chemotherapy [3–7]; however, with first-generation EGFR-TKIs, most patients exhibit disease progression with a median progression-free survival (mPFS) ranging from 9 to 13 months.